ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.9832
0.06%
Brent Oil
83.835
0.25%
Bitcoin
59,534.01
0.70%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Five Prime Therapeutics Inc (FPRX)

  7. Five Prime Therapeutics Inc (FPRX) Noticias

FPRX

Five Prime Therapeutics (FPRX)

Five Prime Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:FPRX
FechaHoraFuenteTítuloSímboloCompañía
15/02/202205:39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FPRXFive Prime Therapeutics Inc
22/04/202105:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FPRXFive Prime Therapeutics Inc
20/04/202110:28TipRanksAmgen Completes The Acquisition Of Five Prime TherapeuticsNASDAQ:FPRXFive Prime Therapeutics Inc
19/04/202118:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202115:16Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202115:02Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202107:48Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202107:43Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202107:39Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202107:38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202107:25PR Newswire (US)Amgen Successfully Completes Acquisition Of Five Prime TherapeuticsNASDAQ:FPRXFive Prime Therapeutics Inc
18/03/202107:02Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:FPRXFive Prime Therapeutics Inc
09/03/202116:00Business WireFive Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference CallNASDAQ:FPRXFive Prime Therapeutics Inc
08/03/202116:02Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:FPRXFive Prime Therapeutics Inc
05/03/202115:20Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:FPRXFive Prime Therapeutics Inc
05/03/202102:57TipRanksAmgen Inks $1.9B Deal To Buy Five Prime Therapeutics; Shares Pop 79%NASDAQ:FPRXFive Prime Therapeutics Inc
04/03/202114:34Dow Jones NewsFive Prime Therapeutics Shares Gain After Amgen DealNASDAQ:FPRXFive Prime Therapeutics Inc
04/03/202108:20Dow Jones NewsAmgen to Acquire Five Prime Therapeutics for $1.9 Billion in CashNASDAQ:FPRXFive Prime Therapeutics Inc
04/03/202107:30PR Newswire (US)Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in CashNASDAQ:FPRXFive Prime Therapeutics Inc
02/03/202115:05Business WireFive Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference CallNASDAQ:FPRXFive Prime Therapeutics Inc
26/02/202116:00Business WireFive Prime Therapeutics to Participate in the Cowen 41st Annual Health Care ConferenceNASDAQ:FPRXFive Prime Therapeutics Inc
22/02/202117:00Business WireFive Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare ConferenceNASDAQ:FPRXFive Prime Therapeutics Inc
16/02/202115:47Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:FPRXFive Prime Therapeutics Inc
05/02/202108:25Business WireFive Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology DayNASDAQ:FPRXFive Prime Therapeutics Inc
15/01/202105:55Business WirePhase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression & Reinforce Potential of Bemari...NASDAQ:FPRXFive Prime Therapeutics Inc
09/12/202016:00Business WireFive Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointe...NASDAQ:FPRXFive Prime Therapeutics Inc
17/11/202016:00Business WireFive Prime Announces Closing of Upsized Public Offering of Common StockNASDAQ:FPRXFive Prime Therapeutics Inc
13/11/202016:28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:FPRXFive Prime Therapeutics Inc
12/11/202021:00Business WireFive Prime Announces Pricing of Upsized Public Offering of Common StockNASDAQ:FPRXFive Prime Therapeutics Inc
12/11/202005:11Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:FPRXFive Prime Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FPRX

Su Consulta Reciente

FX
EURMXN
Euro vs MXN
NYSE
VZ
Verizon Communications
NYSE
MCD
McDonalds
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AAPL
Apple
USOTC
ADDYY
Adidas (QX)
NASDAQ
AMZN
Amazon.com
NYSE
NKE
Nike
SPI
SP500
S&P 500
USI
USTECH100
US Tech 100
NYSE
DIS
Walt Disney
NYSE
BAC
Bank of America
NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados